The glycosylation and orientation in the membrane of the third cytoplasmic loop of human P-glycoprotein is affected by mutations and substrates

被引:14
|
作者
Loo, TW
Clarke, DM
机构
[1] Univ Toronto, Dept Med, MRC, Grp Membrane Biol, Toronto, ON M5S 1A8, Canada
[2] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada
关键词
D O I
10.1021/bi982525y
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Multiple topologies have been detected for the COOH-terminal half of the human multidrug resistance P-glycoprotein (P-gp), In one topology, the predicted third cytoplasmic loop (CL3) is on the cytoplasmic side (P-gp-CL3-cyt) of the membrane. In an alternate topology, CL3 is on the extracellular side of the membrane (P-gp-CL3-ext). It is not known if both forms of P-gp are active because it is difficult to distinguish either topology in the full-length molecule. When the halves of P-gp are expressed as separate polypeptides, the two topologies of the C-Half are readily distinguished on SDS-PAGE, because only the C-Half (CL3-ext) is glycosylated. To rest whether both topologies can fold into an active enzyme, we assayed for interaction between the N- and C-Halves of P-gp since functional P-gp requires interaction between both halves. In a mutant P-gp (E875C) that gave about equal amounts of both topologies, only the C-Half(CL3-cyt) could be recovered by nickel chromatography after coexpression with the histidine-tagged N-Half P-gp. The isolated N-Half and E875C C-Half (CL3-cyt) polypeptides, when expressed together, exhibited verapamil- and vinblastine-stimulated ATPase activities that were similar to the wild-type enzyme. We also found that biosynthesis of mutant E875C C-Half in the presence of the N-Half P-gp resulted in enhanced expression of C-Half(CL3;cyt). By contrast, interaction of C-Half (CL3-ext) with N-Half P-gp was not detected. These results show that the topology of the C-Half portion of P-gp greatly influences its interactions with the amino-terminal half of the molecule.
引用
收藏
页码:5124 / 5129
页数:6
相关论文
共 50 条
  • [41] Interactions of human P-glycoprotein transport substrates and inhibitors at the drug binding domain: Functional and molecular docking analyses
    Kadioglu, Onat
    Saeed, Mohamed E. M.
    Valoti, Massimo
    Frosini, Maria
    Sgaragli, Giampietro
    Efferth, Thomas
    BIOCHEMICAL PHARMACOLOGY, 2016, 104 : 42 - 51
  • [42] Tunicamycin Depresses P-Glycoprotein Glycosylation Without an Effect on Its Membrane Localization and Drug Efflux Activity in L1210 Cells
    Seres, Mario
    Cholujova, Dana
    Bubencikova, Tatiana
    Breier, Albert
    Sulova, Zdenka
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2011, 12 (11): : 7772 - 7784
  • [43] MULTIDRUG RESISTANCE AFTER RETROVIRAL TRANSFER OF THE HUMAN MDR1 GENE CORRELATES WITH P-GLYCOPROTEIN DENSITY IN THE PLASMA-MEMBRANE AND IS NOT AFFECTED BY CYTOTOXIC SELECTION
    CHOI, K
    FROMMEL, TO
    STERN, RK
    PEREZ, CF
    KRIEGLER, M
    TSURUO, T
    RONINSON, IB
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1991, 88 (16) : 7386 - 7390
  • [44] Involvement of phosphatidylinositol-3-kinase in membrane ruffling induced by P-glycoprotein substrates in multidrug-resistant carcinoma cells
    Yang, JM
    Vassil, A
    Hait, WN
    BIOCHEMICAL PHARMACOLOGY, 2002, 63 (05) : 959 - 966
  • [45] Proximity of bound Hoechst 33342 to the ATPase catalytic sites places the drug binding site of P-glycoprotein within the cytoplasmic membrane leaflet
    Qu, Q
    Sharom, FJ
    BIOCHEMISTRY, 2002, 41 (14) : 4744 - 4752
  • [46] Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells
    Schuetz, EG
    Beck, WT
    Schuetz, JD
    MOLECULAR PHARMACOLOGY, 1996, 49 (02) : 311 - 318
  • [47] Clofazimine and B4121 sensitize an intrinsically resistant human colon cancer cell line to P-glycoprotein substrates
    van Rensburg, CEJ
    Jooné, GK
    O'Sullivan, JF
    ONCOLOGY REPORTS, 2000, 7 (01) : 193 - 195
  • [48] Control of P-glycoprotein activity by membrane cholesterol amounts and their relation to multidrug resistance in human CEM leukemia cells
    Gayet, L
    Dayan, G
    Barakat, S
    Labialle, S
    Michaud, M
    Cogne, S
    Mazane, A
    Coleman, AW
    Rigal, D
    Baggetto, LG
    BIOCHEMISTRY, 2005, 44 (11) : 4499 - 4509
  • [49] Processing mutations located throughout the human multidrug resistance P-glycoprotein disrupt interactions between the nucleotide binding domains
    Loo, TW
    Bartlett, MC
    Clarke, DM
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (37) : 38395 - 38401
  • [50] Mutations identified in the human multidrug resistance P-glycoprotein 3 (ABCB4) gene in patients with primary hepatolithiasis
    Kano, M
    Shoda, J
    Sumazaki, R
    Oda, K
    Nimura, Y
    Tanaka, N
    HEPATOLOGY RESEARCH, 2004, 29 (03) : 160 - 166